Us Bancorp \De\ Vaxcyte, Inc. Transaction History
Us Bancorp \De\
- $75.6 Billion
- Q4 2024
A detailed history of Us Bancorp \De\ transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 4,987 shares of PCVX stock, worth $418,110. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,987
Previous 7,042
29.18%
Holding current value
$418,110
Previous $803,000
49.19%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PCVX
# of Institutions
351Shares Held
130MCall Options Held
731KPut Options Held
430K-
Vanguard Group Inc Valley Forge, PA12MShares$1 Billion0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$916 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$833 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$729 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$521 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.97B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...